How does the ER prevent misfolded proteins? Researchers identify the SLC33A1 transporter as a critical glutathione regulator for protein quality control.

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable ...

In the past several years, Rockefeller University's Kivanç Birsoy and his team in the Laboratory of Metabolic Regulation and ...

The GLP-1 weight loss drugs revolutionizing the treatment of obesity, diabetes and a slew of other diseases come with a major ...

Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies. But ...

Specific gene variants (PAM gene) cause GLP-1 resistance in 1 in 10 people, reducing the efficacy of type 2 diabetes drugs.

A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials.

Millions of people have turned to GLP-1 drugs like Ozempic and Wegovy expecting dramatic results. Most get them. But for ...

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana ...

The publication, titled “ Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency” highlights the potential of MG119-28 (formally ...

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that its board of ...

This important study advances a new computational approach to measure and visualize gene expression specificity across different tissues and cell types. The framework is potentially helpful for ...